JPRN-jRCT1041230014招募中2 期
Phase II study of gemcitabine, cisplatin plus durvalumab combination therapy and gemcitabine, cisplatin plus S-1 combination therapy in second or later line for advanced biliary tract cancer
Yamashita Tatsuya0 个研究点目标入组 50 人开始时间: 2023年4月22日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) histologically or cytologically diagnosed as adenocarcinoma or adenosquamous carcinoma
- •2) radiollogically diagnosed as unresectable or recurrent biliary tract cancer
- •3) previously treated by GCS or GCD therapy
- •4) 20 years or older
- •5) ECOG Performance status 0 or 1
- •6) patients capable of oral intake (in GCS group)
- •7) preservation of major organ function
- •8) written informed consent by patient
排除标准
- •1) double cancer
- •2) active infection
- •3) pregnant or lactating women, or women of childbearing potential
- •4) mental disorder
- •5) auto-immune disease
- •6) severe complication
- •7) metastases to central nervous system
- •8) contraindication for the study drug
- •9) patients who investigator regards as inappropriate for candidate
研究者
相似试验
进行中（未招募）
不适用
A Phase 1b/2 Study of Gemcitabine-Cisplatin, With or Without LY2275796 Sodium, in Patients with Advanced Stage IIIB or IV Non-Small Cell Lung Cancer - N/AEUCTR2008-001535-35-FREli Lilly and Company175
已完成
不适用
Phase II trial of gemcitabine and cisplatin in patients with completely resected stage IB-IIIA non-small-cell lung cancer.JPRN-UMIN000000705First Department of Surgery Hamamatsu University School of Medicine20
尚未招募
Unknown
Phase III study of gemcitabine, cisplatin plus S-1 combination therapy versus gemcitabine, cisplatin plus immune checkpoint inhibitor combination therapy in advanced biliary tract cancer.advanced biliary tract cancerJPRN-UMIN000051689Yamaguchi University460
进行中（未招募）
1 期
Randomized phase 2 study of gemcitabine/cisplatin with or without SAR240550(BSI-201), a PARP1 inhibitor, in patients with stage IV non-small cell lung canceron-small cell lung cancer stage IV.MedDRA version: 12.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2009-017270-21-FRsanofi-aventis recherche & développement105
进行中（未招募）
不适用
Randomized phase 2 study of gemcitabine/cisplatin with or without SAR240550(BSI-201), a PARP1 inhibitor, in patients with stage IV non-small cell lung canceron-small cell lung cancer stage IV.MedDRA version: 12.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2009-017270-21-DEsanofi-aventis recherche & développement